Disruptive Approaches To Accelerate Drug Discovery and Development (Part 2) By Dr Anton Fliri, et al. Part 2: Emergent intelligence, a new paradigm for drug discovery. (You can read part 1 of disruptive approaches to accelerate drug discovery and development linked here.) The staggering clinical trial failure rate of experimental… Read More
Precision Medicine Drugs - Pleonasm or Reality? Dr Urban Kiernan and Dr Stephen Naylor The complexity and uniqueness of human metabolism and physiology in the past decade has been highlighted and dissected. Arguments have been made to suggest that our lack of understanding about human individuality has led to the… Read More
Artificial Intelligence & Biopharma R&D IT By The PRISME Forum This article discusses issues around artificial intelligence & Biopharma R&D IT, and outlines how AI can be a potentially transformative technology for the biopharmaceutical and healthcare industries. "...R&D productivity remains an ongoing concern. Artificial Intelligence and the accompanying analytics are… Read More
Bringing Immuno-Oncology Together: How An Immunologist & Oncologist Collaborate By Dr Julia Schuler and Dr Louise Brackenbury For many years, immunology and oncology operated as separate disciplines within drug discovery. However, recent advances in immuno-oncology (IO) have demonstrated what can be achieved when the two disciplines join forces in developing… Read More
The Cancer Conundrum - Increasing Clinical Success In Early Stage Drug Discovery By Lubna Hussain This article focuses on increasing clinical success in early stage drug discovery, by implementing improved methodologies in the early phase & using primary cells and 3D culture models to enhance cancer drug discovery. The high… Read More
Disruptive Approaches To Accelerate Drug Discovery and Development (Part 1) By Ibis Sanchez- Serrano, Dr Tom Pfeifer and Dr Rathnam Chaguturu This article is part 1 of 2, and covers tools, technologies and the core model of disruptive approaches to accelerate drug discovery and development. Tesla intends to implement and… Read More
The Use of Next-Generation Sequencing in Drug Development By Keith Nangle & Mike Furness This article summarises some of the technical and regulatory challenges posed by next-generation sequencing technologies and the efforts being made to address them. Next-generation sequencing (NGS) has moved from the realm of research into those of… Read More
By Dr Simon Moore, Dr Kirsty Harper & Dr Sylwia Marshall The impact and effective routes of non-clinical safety assessment of inhaled biopharmaceuticals. With the rapid generation of biological screening data and the potential for innovative selection of compounds for screening, the importance of multivendor collaborations together with improvements in… Read More
Therapeutic Antibodies - New tools to enhance the antibody drug pipeline By Dr Robert Ford & Dr Toni Hoffmann Therapeutic antibodies are the fastest growing class of drugs, with continuous increases in the number of innovator and biosimilar drugs in development. Drug development and clinical trials necessitate the ability to… Read More
By Paul Avery & Richard Massey Flow cytometry is a powerful tool for cell quantitation and analysis across a wide range of clinical and research applications. Most commonly used in the fields of immunology and haematology, recent improvements in instrument automation and throughput mean that the technique is now emerging… Read More
By Dr Jason Mellad The sequencing of the human genome in 2003 signalled the dawn of an exciting new era for genetic medicine. Yet almost 15 years later it has become clear that our genes alone cannot predict our susceptibility to most complex diseases or fully explain fundamental aspects of… Read More
Phenotypic Screening - Advancing the science from discovery to regulatory science By Dr Ellen L. Berg Phenotypic screening is transforming drug discovery as advances are made in development of human-based physiologically-relevant in vitro systems. Integration of phenotypic drug discovery approaches with target-based screening can improve success rates as assays can… Read More
The Rise of Immunotherapies - Strategies to Accelerate Their Advance Into Clinical Trials By Edward Cribb The striking rise of immunotherapies in the past decade has had a transformative effect on the prospects for the treatment of patients with cancer. Also referred to as biologic therapies, immunotherapies are a new… Read More
New Approaches to Sample Identification Tracking and Technologies for Maintaining Stored Sample Quality By Dr John Comley Safeguarding the quality of stored samples (both compounds and biospecimens) must be the driving ethos in compound management stores and biorepositories. Yet there are few innovations in available sample storage technologies that can… Read More
Raising The Bar On The Biologics Potential Dr Michael Mouradian In the quest for safe, efficacious and profitable therapies, pharma research is changing. There is continued pressure to fill the drug pipeline and, at the same time, globalisation of personalised medicines is complex, expensive and requires a significant time commitment. Read More
Monitoring the Balance Between Immune Repression and Stimulation in Cancer Immunotherapy By Dr Peter Schulz-Knappe and Dr Georg Lautscham Cancer is still one of the main causes of death worldwide, yet recent strides towards more effective treatments have been made in the form of new cancer immunotherapies. By weaponising the… Read More
